Anaesthetic Delivery System- Sedaconda® ACD is intended for administering isoflurane and sevoflurane to invasively ventilated patients. Administration of isoflurane and sevoflurane using Sedaconda® ACD should only be done in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of inhalational anaesthetic drugs and the recognition and management of the expected adverse effects of such drugs, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Sedaconda® ACD is intended for single use only and needs to be replaced every 24 hours or when needed e.g. at unexpected events such as sudden blockage of the airways because of secretion etc. The Sedaconda® ACD is available in Sedaconda® ACD 100 ml and Sedaconda® ACD 50 ml sizes. The instructions contained in this document apply to both devices. Sedaconda® ACD for Small Tidal Volumes and the connection of the Sedaconda® ACD to the inspiratory port of the ventilator. This placement is intended for and enables the delivery of inhaled anaesthetics to patients with tidal volumes of 30 - India CDSCO Medical Device Registration
Anaesthetic Delivery System- Sedaconda® ACD is intended for administering isoflurane and sevoflurane to invasively ventilated patients. Administration of isoflurane and sevoflurane using Sedaconda® ACD should only be done in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of inhalational anaesthetic drugs and the recognition and management of the expected adverse effects of such drugs, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Sedaconda® ACD is intended for single use only and needs to be replaced every 24 hours or when needed e.g. at unexpected events such as sudden blockage of the airways because of secretion etc. The Sedaconda® ACD is available in Sedaconda® ACD 100 ml and Sedaconda® ACD 50 ml sizes. The instructions contained in this document apply to both devices. Sedaconda® ACD for Small Tidal Volumes and the connection of the Sedaconda® ACD to the inspiratory port of the ventilator. This placement is intended for and enables the delivery of inhaled anaesthetics to patients with tidal volumes of 30 is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2023/001172_b417194a3a888b4453d0113c176b1194_0afa972064a65f47f3f707ecfd7d3045. This device is marketed under the brand name Sedaconda®. The license holder is M/s. Hansraj Nayyar Medical India, and it is classified as Device Class Class C. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.
Brand Name
Sedaconda®
License Holder
M/s. Hansraj Nayyar Medical IndiaDevice Class
Approving Authority
CDSCO
Product Information
200 ml. The advantage of the inspiratory side placement is that no dead space is added to the breathing circuit. In contrast to the standard placement of the Sedaconda® ACD (Sedaconda®) the inspiratory side placement only utilises the evaporator function of the Sedaconda® ACD and there is no reflection of inhaled anaesthetic. Therefore, higher inhaled anaesthetic pump rates can be expected than with standard placement, despite lower tidal volumes. Administration of isoflurane and sevoflurane using Sedaconda® ACD should only be done in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of inhalational anaesthetic drugs and the recognition and management of the expected adverse effects of such drugs, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patient airway and assisted ventilation.

